The Company and Summary of Significant Accounting Policies (Details Narrative) - EUR (€)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accumulated deficit	€ (104,416,000)
Current liabilities exceeding current assets	€ 73,408
Preferred stock shares authorized	5,000,000		5,000,000
Potentially shares issuable	811,823,576	775,330,552
Potentially shares issuable convertible loans	786,073,576	749,580,552
Sub award grant revenue USD	€ 3,210
Sub award grant revenue euro	€ 2,900
Basic weighted and diluted	303,757,622	303,757,622
Budget description	The overall budget related to the project is US$8,850 with US$7,131 approved for the period of (May 2019 to April 2023). This includes the funds approved for the period of (May 2022 to April 2023) of US$1,616
Grant allocated description	The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$4,650 approved for the period of (May 2019 to April 2023). This includes the funds approved for the period of (May 2022 to April 2023) of US$1,328
Grant Revenue [Member]
Concentration risk percentage	99.00%	100.00%
First Year [Member]
Sub award grant revenue USD	€ 599
Sub award grant revenue euro	542
Sub award project cost USD	743
Second Year [Member]
Sub award grant revenue USD	1,048
Sub award grant revenue euro	909
Sub award project cost USD	1,519
Third Year [Member]
Sub award grant revenue USD	986
Sub award grant revenue euro	899
Sub award project cost USD	1,078
Fourth Year [Member]
Sub award grant revenue USD	577
Sub award grant deferred revenue USD	550
Sub award project cost USD	815
Five Year [Member]
Sub award grant revenue USD	273
Sub award project cost USD73	€ 288
Stock Option [Member]
Potentially shares issuable	25,750,000	25,750,000